-transparent.png){kind=logo}
Following recent reports suggesting that the addition of cimetidine to interferon may enhance response rates in patients with metastatic malignant melanoma, we have completed a Phase II study of the use of recombinant alpha 2 interferon and cimetidine in patients with advanced malignant melanoma and who had progressive disease following interferon therapy alone. We observed two partial responses, no complete responses, and two patients had stable disease. Toxicity encountered was analogous to that of interferon alone. We conclude that the additional of cimetidine to alpha interferon is not beneficial in the treatment of advanced metastatic malignant melanoma.
Related Publications
T I Mughal, and
W A Robinson, and
M R Thomas, and
R Spiegel
February 1986,
Journal of interferon research,
T I Mughal, and
W A Robinson, and
M R Thomas, and
R Spiegel
October 1997,
Melanoma research,
T I Mughal, and
W A Robinson, and
M R Thomas, and
R Spiegel
February 1983,
The New England journal of medicine,
T I Mughal, and
W A Robinson, and
M R Thomas, and
R Spiegel
April 1988,
European journal of cancer & clinical oncology,
T I Mughal, and
W A Robinson, and
M R Thomas, and
R Spiegel
March 1988,
Cancer,
T I Mughal, and
W A Robinson, and
M R Thomas, and
R Spiegel
January 1984,
Journal of interferon research,
T I Mughal, and
W A Robinson, and
M R Thomas, and
R Spiegel
January 1998,
Oncology,
T I Mughal, and
W A Robinson, and
M R Thomas, and
R Spiegel
August 1995,
Melanoma research,
T I Mughal, and
W A Robinson, and
M R Thomas, and
R Spiegel
June 1993,
Tumori,
T I Mughal, and
W A Robinson, and
M R Thomas, and
R Spiegel
July 1986,
Cancer,
